Moleculin Biotech, Inc. — Form 8-K
Filed October 20, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Moleculin Biotech implemented a 1-for-20 reverse stock split effective October 20, 2026, consolidating approximately 20.9 million shares outstanding into 1.05 million shares. No change to par value ($0.001) or authorized shares (500 million). Fractional shares paid in cash at average closing price over five trading days preceding the split. No material financing, asset, or operational changes disclosed.
Why this rating
Reverse split is routine capital structure action. No new financing, partnerships, or clinical data. Typical of distressed micro-cap—cosmetic, not business-changing.
See more from October 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.